2023 Market Outlook: 15 Top Stock Picks for the New Year
The U.S. stock market is on track for its worst year since 2008, with the S&P 500 down 19.6% year-to-date. The market’s trajectory in 2023 will continue to be dictated by rising...
-
-
Reviewing Healthcare Costs As Driven By Pharma, Hospitals, And Doctors
Another blast from the past before I get into some newer information. It is still very relevant. It lays a foundation for other work I intend to do.
-
2 Stocks to Be Grateful for This Thanksgiving
Rising rates, accelerating inflation, and slowing economy hammered S&P 500 Energy and healthcare shares have been the market’s top gainers Investors should consider buying Exxon...
-
After Rallying 50% in the Last 2 Months, Is Biogen Stock Still a Buy?
Biogen stock is getting favorable ratings after successful trial results for its latest Alzheimer's treatment Lecanemab is Biogen's latest attempt to cure the disease after its failed...
-
Eli Lilly Q3 Earnings And Revenues Beat Estimates
Eli Lilly came out with quarterly earnings of $1.98 per share.
-
1 Stock To Buy, 1 Stock To Dump This Week: Devon Energy, Robinhood
Fed rate hike, U.S. jobs report, more earnings in focus Devon Energy stock is a buy with strong Q3 earnings ahead Robinhood set to struggle amid shrinking revenue, fewer MAUs Stocks on Wall...
-
2 Leaders Breaking Out To New All-Time Highs Worth Adding To Your Portfolio
Energy and healthcare stocks have been some of this year’s top gainers Consider buying ConocoPhilips, and Eli Lily Even as the S&P 500 has plunged into bear market territory,...
-
Johnson & Johnson: Hard To Sell And Tough To Own
It remains difficult to bet against J&J in the long term Near-term challenges around currency and inflation will linger into 2023 Investors probably shouldn’t rush to sell shares,...
-
Plan Now For When The U.S. Fed Beats Inflation
Let's be frank: The third quarter was a mess for stocks. It doesn't much matter where the stocks were traded, except this: U.S. stocks in September were not a place you wanted to be. The Dow...
-
Should You Buy Eli Lilly Stock As Drugmaker Continues To Outperform Benchmarks?
Eli Lilly stock is looking expensive following its substantial gains in recent years There are also some signs that sales are weakening due to the falling demand for COVID treatments and...
-
2 Vanguard ETFs For Diversification This Earnings Season
Investors looking for low cost exchange funds (ETFs) typically put those offered by Vanguard high on their radar screen. In terms of ETF assets under management (AUM), the investment...
-
2 Equal-Weight ETFs To Avoid Portfolio Concentration Ahead Of Earnings Season
Equal-weight exchange-traded funds (ETFs) invest roughly an equal percentage in each company within their portfolios, thus avoiding concentration. By doing so, these ETFs provide...
-
3 Healthcare Giants Bucking The Bear Market
Healthcare stocks have been some of this year’s best performers Defensive, blue-chips with reasonable valuations and strong dividends tend to do well in a bear market Consider buying...
-
Pfizer: 3 Trades To Buy Into Cash Rich Pharma Giant
Shares of Pfizer are down over 12.5% since the start of 2022. Plan to spend cash generated from COVID-19 vaccine on M&As and share buybacks. Long-term investors may consider buying PFE...
-
2 Health Care And Biotech ETFs Poised For Robust Returns This Year
The COVID-19 pandemic highlighted the importance of health care and the role biopharma companies play in drug and vaccine development. As a result, the sector grew tremendously during the...
-
3 Recession-Proof Stocks To Protect Your Portfolio From Fed-Induced Turmoil
Fed's expected aggressive tightening to contain soaring inflation, has many worrying about a possible recession. Three companies to protect your portfolio due to strong fundamentals,...
-
2 ETFs For Weathering Growing Recession Risks
Wall Street is debating whether a recession or a significant downturn could be on the horizon for the US and the global economy. Recently, Goldman Sachs suggested that the odds of such an...
-
2 Safe ETFs For Passive Income Investors
February started on a higher note. But after January's rout on Wall Street, volatility looks poised to persist, at least for the next few weeks. As a consequence, many investors are looking...
-
3 Trades On Eli Lilly Stock As Pharma Investors Await Q4 Results
LLY, one of the best-performing pharma stocks in 2021, was down over 6% in the first week of the new year. Wall Street concurs that innovation across its core therapeutic areas has meant...
-
3 Year-To-Date Winners Set For More Highs As Omicron Fears Jolt Markets
Global financial markets are being whipsawed this week. Stocks on Wall Street have been suffering one of their worst selloffs of the year, as concerns over the spread of the Omicron...
-
2 ETFs That Could See Better Days In December
The final week of November brought increased volatility to broader markets. But when looking at the year as a whole, so far the Dow Jones, the S&P 500 and the NASDAQ 100 are up 12.9%,...
-
Concerned About Volatility In AbbVie Stock? Try A 'Poor Person's Covered Call'
Leading pharma group AbbVie (NYSE:ABBV) issued robust {{erl-40041||Q2 metrics in late July. However, since then, ABBV stock has been volatile. Between July 30 and Aug. 10, the shares...
-
Cipla may be Re-Rated for Probable Commercial JV with Moderna’mRNA COVID Vaccine
Cipla (NS:CIPL) may be Re-Rated for Probable Commercial JV with Moderna’Next-Generation mRNA COVID Vaccine and Tech to Treat Other Critical DiseasesCipla is a major Indian...
-
Promise Of ECB Largesse Buoys European Government Bonds
What a difference a decade makes. Portuguese government 10-year bonds are heading for a yield of 0%, compared to 16% at the height of the eurozone debt crisis in 2012 and 4% as recently as...
-
As Indices Rise To Records, More And More Individual Stocks Sink
This article was written exclusively for Investing.comThe S&P 500 advanced to a record close on Aug. 18, completely erasing the March sell-off. But, despite the appearance of a healthy stock...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
